Valeant buys clout with skincare lines
Canada’s largest publicly traded drug company is about to get a whole lot bigger, thanks to zit cream and aging faces.
News & Media
Cangene Announces Agreement to Sell U.S. Plasma Centres
Cangene Corporation (Cangene) today announces that its wholly owned subsidiary, Cangene Plasma Resources, Inc. has entered into an agreement for the sale of its three U.S. based plasma centres to Grifols, through wholly owned Grifols subsidiary, Biomat US
IMRIS Announces Allowance of US Patent in MR Guided Radiation Therapy And First Product Clearance in Their Image Guided Radiation Therapy Business
The recently cleared MR imaging radiation oncology package is for pelvic, brain, and head and neck imaging.
Increasing Utilization of Food Processing Side Streams Key to Improving Health and Sustaining Production
Increasing Utilization of Food Processing Side Streams Key to Improving Health and Sustaining…
FibreCity takes another step toward reality
Feds give $860K to future test facility
Canada punches above its weight in HIV vaccine research
Many Canadians don't know it but Canada is a major contributor to global efforts to develop an HIV vaccine.
Harder Exercise Tied to Lower Heart Risk in Kids
Vigorous physical activity -- as opposed to less-intense exercise -- appears to be key in reducing cardiometabolic risk in children and teens
Patheon sells secondary clinical packaging, distribution business to Bellwyck
Contract pharmaceutical company Patheon Inc. is selling its global secondary clinical packaging and clinical distribution services business
Valeant bets on anti-aging boom with Medicis takeover bid
Valeant Pharmaceuticals announced that it is acquiring Medicis Pharmaceutical for $44.00 per share in cash, in a deal valued at about $2.6 billion.
Cangene announces continuation of biodefence programs with U.S. Government
Cangene Corporation (Cangene) announced today the extension of an existing contract and the signing of a new contract related to United States Government biodefence programs. The Company continues to leverage its expertise in biodefence contracting to su
1 flu shot for the rest of your life?
Researchers at the National Microbiology Laboratory in Winnipeg are working on a new universal flu vaccine.
Business on the cheap
A growing number of companies are looking for cheaper locations to set up shop, and Winnipeg could be one of the big benefactors of that trend.
EDC commits CAD 7.5 M to venture capital fund for Canadian food and agricultural companies.
Export Development Canada (EDC) today announced its commitment to invest up to CAD 7.5 million in Avrio Ventures Limited Partnership II (Avrio II), a venture capital fund investing in innovative food and agricultural companies that provide solutions to gl
Alere Secures Final Option Period on Miraculins’ Preeclampsia Technology
Research and Development Program to Focus on Select Set of Biomarkers
Cangene signs deal to bring Episil to American market
Cangene has entered into an agreement with Camurus AB for exclusive rights to commercialize Episil in the United States.
Harper Government Supports New Food Science Technologies at Red River College
Manitoba's food industry will soon gain an advantage thanks to Harper Government funding announced today by the Honourable Lynne Yelich, Minister of State for Western Economic Diversification.
Cash scarce for Manitoba entrepreneurs
There is an acute awareness of the issue in the community and a mobilization of energies is underway.
Scientists announce groundbreaking discovery in treating Ebola virus
Scientists at the National Microbiology Laboratory in Winnipeg believe they’ve made a groundbreaking discovery in the treatment of the deadly Ebola virus
Miraculins Launches New Canadian Web Site for PreVu®
Online Platform Designed for Healthcare Professionals and Public/Consumers.
Manitoba Plays Key Role in Global Action to Improve Public Health with Whole Grains
300 global leaders from health and food industry sectors met to work together towards the common goal of bringing business goals into alignment with public health goals at the Whole Grains Summit.
Lilly invests in $150 million Canada life sciences fund
Eli Lilly is participating in a new investment fund which will focus primarily on early-stage drug development opportunities in Canada as a whole and Quebec in particular.